BRIEF-Senti Bio Announces Positive Initial Clinical Data In Phase 1 Clinical Trial Of Senti-202, A Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy For The Treatment Of Relapsed/Refractory Hematologic Malignancies Including AML

Reuters
02 Dec 2024
BRIEF-Senti Bio Announces Positive Initial Clinical Data In Phase 1 Clinical Trial Of Senti-202, A Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy For The Treatment Of Relapsed/Refractory Hematologic Malignancies Including AML

Dec 2 (Reuters) - Senti Biosciences SNTI.O:

  • SENTI BIO ANNOUNCES POSITIVE INITIAL CLINICAL DATA IN PHASE 1 CLINICAL TRIAL OF SENTI-202, A LOGIC GATED, SELECTIVE CD33/FLT3-TARGETING CAR-NK CELL THERAPY FOR THE TREATMENT OF RELAPSED/REFRACTORY HEMATOLOGIC MALIGNANCIES INCLUDING AML

  • SENTI BIOSCIENCES INC - SENTI-202 GENERALLY WELL-TOLERATED WITH CONSISTENT ADVERSE EVENT PROFILE

  • SENTI BIOSCIENCES INC - DOSE ESCALATION CONTINUING, ADDITIONAL DATA EXPECTED IN 2025

Source text: ID:nGNX4XG7dt

Further company coverage: SNTI.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10